Company intelligence / Profile preview

Rheoscience

Rødovre/Copenhagen area, Denmarkpharmexcil.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Lead compound balaglitazone showed significant reduction in HbA1c and improved safety profile compared to comparator in a Phase III trial for type 2 diabetes. The company also had a profitable contract research business focused on metabolic diseases. No recent clinical results available after ~2010.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

balaglitazone

Partnerships

Dr. Reddy's Laboratories (co-development and commercialization agreement for balaglitazone/DRF2593; Dr. Reddy's retained US/rest-of-world rights, Rheoscience retained EU/China rights)

Beyond the preview

Go deeper on Rheoscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rheoscience.

Explore the full profile